Sign in
Taking people in United StatesNo phase

Red light before home walking exercise for peripheral artery disease

Tests far red light before walking exercise in people with peripheral artery disease.

Key facts

Who runs it
Northwestern University
Where
Chicago, United StatesSee the site
Trial code
Registry title
ENhancing Exercise With LIGHT to Improve Functioning in PAD
Status
Recruiting
People taking part
32 people, planned
Started
12 Aug 2024
Expected to end
31 Jan 2027
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Far red light therapy
  • Sham light therapy
  • Home-based walking exercise
Record updated
15 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 and older with peripheral artery disease (PAD) in the legs. It tests red light on the legs before home walking exercise, compared to a fake (sham) light.

Age
50 years and older
Sex
All sexes
Disease stage
Lower leg peripheral artery disease (narrowed leg arteries). People with critical limb ischemia (ABI <0.40 with pain at rest) cannot join.
Earlier treatment
No supervised treadmill exercise or cardiac rehabilitation program in the previous three months. No major surgery, coronary or leg revascularization (procedure to restore blood flow) in the previous three months. No clinical trial in the previous three months.
Biomarker or test result
One of these: an ABI (ankle-arm blood pressure ratio) <= 0.90; vascular lab evidence such as toe brachial pressure <= 0.70; at least 70% narrowing of a leg artery on angiography; or an ABI >0.90 and <= 1.00 that drops 20% or more after a heel-rise test.

Main reasons for not taking part

  • Above- or below-knee amputation, wheelchair use, or needing a walker
  • Walking limited by something other than PAD, or six-minute walk distance of <400 feet or >1700 feet
  • Current foot ulcer on the bottom of the foot
  • Major illness such as lung disease needing oxygen, Parkinson's disease, or cancer needing treatment in the previous two years
  • Planned major surgery or leg or heart artery procedure in the next four months, or MMSE (memory test) score < 23

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • First, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as:
  • An ABI <= 0.90 at baseline
  • Vascular lab evidence of PAD (such as a toe brachial pressure <= 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities
  • An ABI of >0.90 and <= 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test

Who cannot take part

  • Planned major surgery, coronary or leg revascularization during the next four months
  • Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months
  • Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent, unless the cancer is located in the lower extremities. Participants who require oxygen only at night may still qualify.]
  • Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.]
  • Participation in a supervised treadmill exercise program or a cardiac rehabilitation program in previous three months or planning to begin a supervised treadmill exercise program or a cardiac rehabilitation program in the next five months
  • Unwilling to avoid red light therapy outside of study participation
  • Current foot ulcer on bottom of foot
  • Failure to successfully complete the study run-in
  • Visual impairment that limits walking ability
  • Above- or below-knee amputation
  • Critical limb ischemia defined as an ABI <0.40 with symptoms of rest pain
  • Wheelchair confinement or requiring a walker to ambulate
  • Walking is limited by a symptom other than PAD
  • Mini-Mental Status Examination (MMSE) score < 23
  • Non-English speaking
  • Six-minute walk distance of <400 feet or >1700 feet
  • Baseline blood pressure <100/45
  • In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant

Where in United States

  • Northwestern UniversityChicago, United StatesContact: Mary McDermott, MDTaking people

About the trial

What the trial wants to find out

The ENLIGHTEN PAD Trial will collect preliminary data to test whether daily 660 nm light treatment of the lower extremities immediately before home-based walking exercise sessions improves six-minute walk distance at 4-month follow-up, compared to sham light, in people with lower extremity peripheral artery disease (PAD).

The 2 groups in the trial

  • Far red light therapy + home-based walking exerciseTreatment being tested

    Subgroup of participants receiving home-based walking exercise and the 670 nm far red light device

    Treatment: Far red light therapy and Home-based walking exercise

  • Sham therapy + home-based walking exerciseSham treatment, for comparison

    Subgroup of participants receiving home-based walking exercise and the sham light device, far red light device covered with blue filter paper to block 670 nm light, resulting in mean power generated of 0.24 mW/cm2, compared to 26.3 mW/cm2 for the intervention, a 100-fold difference.

    Treatment: Sham light therapy and Home-based walking exercise

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ENhancing Exercise With LIGHT to Improve Functioning in PAD: the ENLIGHTEN PAD Trial
Plain-language title
Red light before home walking exercise for peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
15 April 2026